曾凭借"小葵花妈妈课堂开课啦"实现国民级营销神话的葵花药业，正深陷转型阵痛。 近日，葵花药业发布全年业绩预告，2025年业绩预亏，归母净利润为-3.80亿元至-2.40亿元，同比下降 177.23%至148.78%，扣非归母净利润为-4.2亿元至-2.85亿元，迎来2014年上市以来的首次年度亏损。 事实上，在2023年业绩达到巅峰后，葵花药业已连续两年业绩承压。2023年，其营收达到57亿元，归母 净利润在同比增加29.05%后达11.19亿元。而2024年，公司业绩急转直下，营收大幅下滑40.76%，归母 净利润腰斩至4.92 亿元，2025年亏损态势进一步延续。 业内认为，葵花药业当前的发展困境，主要源于此前广告驱动、渠道压货的传统营销模式遗留弊端。该 粗放式营销模式曾是企业发展的重要依托，但如今已成为束缚发展的枷锁。葵花药业也在试图转型，但 过程并不容易，需要承受相应的代价。 业绩首亏 葵花药业前身是原黑龙江省国有五常制药厂，1998年改制为民营企业，随后不断发展壮大，于2005年组 建葵花药业集团股份有限公司。2014年底，葵花药业正式登陆深交所，迎来新发展阶段。 凭借"小葵花"卡通形象和高辨识度的 ...

证券代码：002737 证券简称：葵花药业 公告编号：2026-003 葵花药业集团股份有限公司 关于收到易活牌益生菌粉 注册申请受理通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 登录新浪财经APP 搜索【信披】查看更多考评等级 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）全资子公司 哈尔滨葵花药业有限公司于近 日收到国家市场监督管理总局下发的关于"易活牌益生菌粉"注册申请的《受理通知书》，现将有关情况 公告如下： 一、产品的基本情况 产品名称：易活牌益生菌粉 受理号：国食健申G20260026 申请事项：国产保健食品新产品注册 申请人：哈尔滨葵花药业有限公司 结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以受理。 产品功能：本品经动物实验评价，具有有助于增强免疫力的保健功能;有助于润肠通便。 二、风险提示 上述产品在收到国家市场监督管理总局注册申请受理后，将转入国家市场监督管理总局保健食品审评机 构进行审评审批，鉴于产品审评周期长、环节多，期间受不确定性因素影响，具体完成时间、审批结果 存在不确定性。提醒广 ...

Core Viewpoint - The company is committed to driving high-quality development through systematic reforms, including organizational optimization, model upgrades, team restructuring, and cultural revival [1] R&D Innovation - The company is implementing a distinctive R&D strategy characterized by "buy, modify, connect, and research" to continuously optimize its product structure, injecting core momentum for long-term development [1] Brand Building - The company aims to strengthen brand creation and promotional efforts to enhance brand value and increase the market traction of its core brands [1] Marketing Breakthrough - The company is executing a combination marketing strategy of "brand pull, prescription lead, OTC push, and guerrilla team capture" to reshape its leading position in the OTC sector and drive performance recovery and steady development from multiple dimensions [1]

Core Viewpoint - The company, Kew Flower Pharmaceutical (葵花药业), is committed to a distinctive research and development strategy focusing on specific areas such as elderly care, pediatrics, and women's health, with plans to achieve multiple R&D milestones by 2025 [1] Group 1: R&D Strategy - The company adheres to a "buy, modify, connect, and research" strategy to enhance its product pipeline [1] - Continuous and long-term investments are made in targeted areas to enrich the product line [1] Group 2: Product Development - By 2025, the company expects to obtain drug registration certificates for several products, including Ibuprofen Suspension Drops, Polyethylene Glycol 3350 Powder, and others [1] - The company is expanding its portfolio in the elderly pain management sector through collaborative R&D projects [1] - The company has acquired production licenses and related technologies for several drugs, further enhancing its product categories [1] Group 3: Market Position - Multiple applications for drug and health product registration have been accepted, indicating a proactive approach to market expansion [1]

Group 1 - Far East Holdings announced that its subsidiary won a contract order worth 3.075 billion yuan, including contracts for green building cables and smart manufacturing cables [1] - Yifan Pharmaceutical received a drug registration certificate for Vitamin K1 injection, which is used to treat vitamin K deficiency-related bleeding [2] - Guangdong Electric Power A's Maoming Bohua Power Plant's Unit 4 has successfully commenced commercial operation, with a total investment of 7.484 billion yuan and an expected annual power generation of 8.6 billion kWh [4] Group 2 - Longfly Fiber reported that the global fiber optic cable industry market environment is normal, with product price fluctuations needing comprehensive assessment [25] - Shanghai Yizhong's net profit for 2025 increased by 819.42%, with total revenue of 317 million yuan, a growth of 82.72% [22] - Guizhou Power's subsidiary received a government subsidy of 200 million yuan [8] Group 3 - Zhongxing Communications plans to invest 117 million yuan in the Jianxing Zhanlu Fund, which focuses on new information technology and advanced manufacturing [10] - Suwen Electric Power's subsidiary established a joint investment fund with a total commitment of 68.5 million yuan, with Suwen contributing 5 million yuan [26] - ST Kaiyuan announced that its stock may face delisting risk due to expected negative net assets for 2025 [27]

Core Viewpoint - Kweichow Moutai's subsidiary Harbin Kweichow Moutai Pharmaceutical Co., Ltd. has received a notice of acceptance for the registration application of "Yihuo Probiotic Powder" from the State Administration for Market Regulation, indicating potential health benefits related to immune enhancement and bowel regulation [1] Group 1 - The product "Yihuo Probiotic Powder" has undergone animal testing and has been evaluated for its health functions [1] - The product is positioned to assist in enhancing immunity and promoting bowel movement [1]

公告称，本品经动物实验评价，具有有助于增强免疫力的保健功能;有助于润肠通便。 葵花药业（002737）(002737.SZ)公告，公司全资子公司哈尔滨葵花药业有限公司于近日收到国家市场 监督管理总局下发的关于"易活牌益生菌粉"注册申请的《受理通知书》。 ...

智通财经APP讯，葵花药业(002737.SZ)公告，公司全资子公司哈尔滨葵花药业有限公司于近日收到国家 市场监督管理总局下发的关于"易活牌益生菌粉"注册申请的《受理通知书》。 公告称，本品经动物实验评价，具有有助于增强免疫力的保健功能;有助于润肠通便。 ...

葵花药业公告，全资子公司哈尔滨葵花药业有限公司近日收到国家市场监督管理总局下发的关于"易活 牌益生菌粉"注册申请的《受理通知书》。产品名称为易活牌益生菌粉，受理号为国食健申 G20260026，申请事项为国产保健食品新产品注册，产品功能经动物实验评价，具有有助于增强免疫力 和润肠通便的保健功能。 ...

证券代码：002737 证券简称：葵花药业 公告编号：2026-003 葵花药业集团股份有限公司 关于收到易活牌益生菌粉 注册申请受理通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）全资子公司 哈尔滨葵花药业有限公司于近日收到国家市场监督管理总局下发的关于"易活牌 益生菌粉"注册申请的《受理通知书》，现将有关情况公告如下： 一、产品的基本情况 产品名称：易活牌益生菌粉 受理号：国食健申 G20260026 申请事项：国产保健食品新产品注册 结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决 定予以受理。 产品功能：本品经动物实验评价，具有有助于增强免疫力的保健功能;有助 于润肠通便。 二、风险提示 上述产品在收到国家市场监督管理总局注册申请受理后，将转入国家市场监 督管理总局保健食品审评机构进行审评审批，鉴于产品审评周期长、环节多，期 间受不确定性因素影响，具体完成时间、审批结果存在不确定性。提醒广大投资 者审慎决策，注意投资风险。 1 公司将积极推进新产品注册工作并持续关注 ...